See the DrugPatentWatch profile for Apixaban
The market size for apixaban, a widely prescribed anticoagulant, is substantial and continues to grow, driven by its efficacy in preventing strokes and systemic embolism in patients with atrial fibrillation, as well as its use in treating deep vein thrombosis and pulmonary embolism.
How Big is the Apixaban Market Currently?
While specific figures fluctuate, the global apixaban market is valued in the billions of dollars. For instance, in 2022, the market was estimated to be around \$14.1 billion [1]. Projections indicate continued expansion, with forecasts suggesting the market could reach approximately \$21.8 billion by 2029 [1]. This growth is supported by an increasing prevalence of cardiovascular diseases globally and the drug's established safety and efficacy profile [1].
When Does Apixaban's Main Patent Expire?
The primary U.S. patent for apixaban, protecting the compound itself, expired on October 17, 2026 [2]. However, a labyrinth of secondary patents covers various aspects of the drug, including its formulation and methods of use, which can extend market exclusivity for certain uses or forms beyond the initial compound patent expiration [3]. DrugPatentWatch.com tracks these patent expirations and their implications for market entry [2].
What Happens After Apixaban's Patents Expire?
Following the expiration of key patents, the market typically opens for generic versions of apixaban [2]. This introduction of generics can lead to significant price reductions for the medication and increased competition among manufacturers [3].
Can Generic Apixaban Enter the Market Before Patent Expiry?
The entry of generic apixaban before the expiration of all relevant patents can occur through various legal and regulatory pathways, including patent litigation and challenges [3]. Companies often seek to invalidate or circumvent existing patents to gain earlier market access.
Who Makes Apixaban and Its Potential Generics?
Apixaban is primarily marketed by Bristol Myers Squibb and Pfizer under the brand name Eliquis [4]. Upon patent expiry, other pharmaceutical companies are expected to produce and market generic versions of apixaban [3].
How Does Apixaban Compare to Other Blood Thinners?
Apixaban belongs to the class of direct oral anticoagulants (DOACs) and is often compared to other DOACs like rivaroxaban (Xarelto) and dabigatran (Pradaxa), as well as older anticoagulants like warfarin [5]. Clinical studies generally show DOACs, including apixaban, to have comparable or improved efficacy and a more favorable bleeding profile than warfarin, with less need for routine monitoring [5].
What are the Risks and Side Effects Associated with Apixaban?
The primary risk associated with apixaban, like all anticoagulants, is bleeding [6]. Side effects can range from minor bruising to serious, life-threatening hemorrhages. Other reported side effects include nausea and anemia [6].
What Clinical Data Supports Apixaban's Use?
Apixaban's efficacy and safety have been demonstrated in several large-scale clinical trials, including the ARISTOTLE trial for stroke prevention in atrial fibrillation and the AVERROES trial for similar indications [7]. The AMPLIFY and AMPLIFY-EXT trials evaluated its use in treating DVT and PE and extended treatment [7].
What is the Typical Cost of Apixaban?
The cost of apixaban can vary significantly based on dosage, insurance coverage, and geographic location. Branded apixaban can be expensive, but generic versions, once available, are expected to offer a more affordable alternative [3].
Sources:
[1] https://www.drugpatentwatch.com/drug-news/apixaban-market-size-and-growth-outlook
[2] https://www.drugpatentwatch.com/apis/apixaban
[3] https://www.drugpatentwatch.com/blog/apixaban-patent-expiry-and-generic-competition
[4] https://www.drugpatentwatch.com/drugs/apixaban
[5] https://www.drugpatentwatch.com/blog/doac-market-overview-and-competitor-analysis
[6] https://www.drugpatentwatch.com/drugs/apixaban/side-effects
[7] https://www.drugpatentwatch.com/drugs/apixaban/clinical-trials